Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Pre-Menopausal Women

The Women's Health Research Unit is conducting a study to evaluate the safety and effectiveness of a new investigational medication to manage heavy menstrual bleeding associated with uterine fibroids.

AbbVie Fibroid Woman Image

Why is this study being done?

Uterine fibroids (leiomyomata) are benign tumors or growths in the uterus (womb) and are symptomatic in approximately 20% to 50% of women. Symptoms can include heavy menstrual bleeding, pelvic pressure, bloating, and pelvic pain. One of the main symptoms of uterine fibroids is heavy menstrual bleeding (HMB). The study drug is being investigated as a new medication option for the management of heavy menstrual bleeding associated with uterine fibroids.

This study will look at the study drug using two randomly assigned treatment groups. One group will receive a placebo (a pill that looks like the study drug but does not have medication in it). The study will take up to 53 months to complete.

 

Eligibility:

  • Women between the ages of 18-48 years of age
  • Currently pre-menopausal
  • Have Uterine Fibroids
  • Have heavy menstrual bleeding associated with Uterine Fibroids.
  • Additional eligibility criteria will be reviewed during early screening to determine eligibility to participate in this study.

Compensation 

Qualified participants will be compensated up to $2,675 for time and travel. Study participation involves 17 in person visits to the OHSU Marquam Hill campus clinic.